| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcome
|
Chen, Yiyang
|
|
|
4 |
20 |
p. 5257-5268
|
artikel
|
| 2 |
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
|
Chaekal, Ok-kyong
|
|
|
4 |
20 |
p. 5146-5156
|
artikel
|
| 3 |
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide
|
Webster, Jonathan A.
|
|
|
4 |
20 |
p. 5078-5088
|
artikel
|
| 4 |
Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause
|
Mehic, Dino
|
|
|
4 |
20 |
p. 5157-5164
|
artikel
|
| 5 |
Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study
|
Saes, Joline L.
|
|
|
4 |
20 |
p. 5025-5034
|
artikel
|
| 6 |
Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide
|
Solomon, Scott R.
|
|
|
4 |
20 |
p. 5311-5321
|
artikel
|
| 7 |
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
|
Morrish, Emma
|
|
|
4 |
20 |
p. 5062-5077
|
artikel
|
| 8 |
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
|
Scholze, Hanna
|
|
|
4 |
20 |
p. 5226-5231
|
artikel
|
| 9 |
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
|
Herrmann, Harald
|
|
|
4 |
20 |
p. 5118-5132
|
artikel
|
| 10 |
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
|
Diorio, Caroline
|
|
|
4 |
20 |
p. 5174-5183
|
artikel
|
| 11 |
Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong
|
Lee, Shing Fung
|
|
|
4 |
20 |
p. 5107-5117
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
4 |
20 |
p. i
|
artikel
|
| 13 |
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
|
Visani, Giuseppe
|
|
|
4 |
20 |
p. 5040-5049
|
artikel
|
| 14 |
Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies
|
Trottier, Amy M.
|
|
|
4 |
20 |
p. 5269-5284
|
artikel
|
| 15 |
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
|
Nehme, Ali
|
|
|
4 |
20 |
p. 5322-5335
|
artikel
|
| 16 |
Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes
|
Oved, Joseph H.
|
|
|
4 |
20 |
p. 5232-5245
|
artikel
|
| 17 |
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment
|
Shen, Yandong
|
|
|
4 |
20 |
p. 5093-5106
|
artikel
|
| 18 |
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells
|
Amatore, Florent
|
|
|
4 |
20 |
p. 5203-5214
|
artikel
|
| 19 |
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab
|
Krishnan, Amrita
|
|
|
4 |
20 |
p. 5194-5202
|
artikel
|
| 20 |
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
|
Osman, Mohammed
|
|
|
4 |
20 |
p. 5035-5039
|
artikel
|
| 21 |
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia
|
Ueno, Hiroo
|
|
|
4 |
20 |
p. 5165-5173
|
artikel
|
| 22 |
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses
|
Morgan, Rebecca L.
|
|
|
4 |
20 |
p. 5184-5193
|
artikel
|
| 23 |
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
|
Yonekura, Kentaro
|
|
|
4 |
20 |
p. 5133-5145
|
artikel
|
| 24 |
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report
|
Brodersen, Lisa Eidenschink
|
|
|
4 |
20 |
p. 5050-5061
|
artikel
|
| 25 |
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia
|
Castillo, Jorge J.
|
|
|
4 |
20 |
p. 5089-5092
|
artikel
|
| 26 |
Next-generation sequencing of 35 RHD variants in 16 253 serologically D− pregnant women in the Finnish population
|
Tammi, Silja M.
|
|
|
4 |
20 |
p. 4994-5001
|
artikel
|
| 27 |
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
|
Calvo, Xavier
|
|
|
4 |
20 |
p. 5285-5296
|
artikel
|
| 28 |
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
|
Mascarenhas, John O.
|
|
|
4 |
20 |
p. 5246-5256
|
artikel
|
| 29 |
Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis
|
Bosch, Floris T.M.
|
|
|
4 |
20 |
p. 5215-5225
|
artikel
|
| 30 |
Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
|
Barnkob, Mike Bogetofte
|
|
|
4 |
20 |
p. 4990-4993
|
artikel
|
| 31 |
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy
|
Islam, Shariful
|
|
|
4 |
20 |
p. 5297-5310
|
artikel
|
| 32 |
Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis
|
Fronas, Synne G.
|
|
|
4 |
20 |
p. 5002-5010
|
artikel
|
| 33 |
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
|
Hoiland, Ryan L.
|
|
|
4 |
20 |
p. 4981-4989
|
artikel
|
| 34 |
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
|
Vadakekolathu, Jayakumar
|
|
|
4 |
20 |
p. 5011-5024
|
artikel
|
Tijdschrift beschrijving